Search

Showing total 25 results

Search Constraints

Start Over You searched for: Search Limiters Academic (Peer-Reviewed) Journals Remove constraint Search Limiters: Academic (Peer-Reviewed) Journals Topic therapeutics Remove constraint Topic: therapeutics Publication Year Range Last 3 years Remove constraint Publication Year Range: Last 3 years Journal alimentary pharmacology & therapeutics Remove constraint Journal: alimentary pharmacology & therapeutics Publisher wiley-blackwell Remove constraint Publisher: wiley-blackwell
25 results

Search Results

1. Monitoring disease progression in metabolic dysfunction‐associated steatotic liver disease.

6. Letter: non‐invasive transabdominal stimulation device for the treatment of chronic constipation—proof‐of‐principle study in adults.

8. Letter: non‐invasive transabdominal stimulation device for the treatment of chronic constipation—proof‐of‐principle study in adults. Authors' reply.

10. Editorial: protecting hypoxia‐inducible factor 1a and gut integrity with GB004—a promising therapeutic approach for ulcerative colitis? Authors' reply.

12. Editorial: targeting aberrant hepatic inflammation for treatment of non‐alcoholic steatohepatitis—authors' reply.

16. Editorial: bezafibrate in the treatment of patients with primary biliary cholangitis—are we there yet? Authors' reply.

18. Editorial: does anti‐TNF 'treatment persistence' always equate to 'effective treatment'? Only objective disease assessments can answer the question. Authors' reply.

20. Editorial: recognising the efficacy of licensed drug therapies for irritable bowel syndrome on bloating—a step in the right direction for targeted treatment? Authors' reply.

22. Editorial: on the road towards treatment of gastroparesis—accelerating, but do we get closer? Authors' reply.

24. Editorial: total anti‐drug antibodies detected using drug‐tolerant assays during induction with anti‐TNF therapy are associated with treatment failure—out of sight but not out of mind. Authors' reply.

25. Editorial: total anti‐drug antibodies detected using drug‐tolerant assays during induction with anti‐TNF therapy are associated with treatment failure—out of sight but not out of mind.